System and method for performing renal denervation verification

ABSTRACT

A renal denervation feedback method is described that performs a baseline measurement of renal nerve plexus electrical activity at a renal vessel; denervates at least some tissue proximate the renal vessel after performing the baseline measurement; performs a post-denervation measurement of renal nerve plexus electrical activity at the renal vessel, after the denervating; and assesses denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. patent application Ser. No. 13/248,818, filed on Sep. 29, 2011, the entire contents and disclosure of which are hereby incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

The present invention relates generally to denervation, and more specifically to systems and methods for renal denervation verification and feedback.

Hypertension (HTN), or high blood pressure (HBP), is defined as a consistently elevated blood pressure (BP) greater than or equal to 140 mmHg systolic blood pressure (SBP) and 90 mmHg diastolic blood pressure (DBP). Hypertension is a “silent killer” that is not associated with any symptoms and in 95% of cases (primary hypertension) the specific cause is unknown. In the remaining 5% of patients (secondary hypertension), specific causes including chronic kidney disease, diseases of the adrenal gland, coarctation of the aorta, thyroid dysfunction, alcohol addiction, pregnancy or the use of birth control pills are present. In secondary hypertension, when the root cause is treated, blood pressure usually returns to normal.

Hypertension is a disease that affects 74.5 million patients in the US with 24% or 17.7 million patients classified as uncontrolled hypertensive patients. Of these 17.7 million US patients, 27% of them are resistant to drug therapy without any secondary causes. This equates to 4.8 million patients in the US and an estimated 12.4 million patients outside of the US for a total of 17.2 million patients worldwide. Needless to say, there is a need for additional therapeutic options for this class of unsuccessfully treated patients.

It is generally accepted that the causes of hypertension are multi-factorial, with a significant factor being the chronic hyper-activation of the sympathetic nervous system (SNS), especially the renal sympathetic nerves. Renal sympathetic efferent and afferent nerves, which lie in the wall of the renal artery, have been recognized as a critical factor in the initiation and maintenance of systemic hypertension. Renal arteries, like all major blood vessels, are innervated by perivascular sympathetic nerves that traverse the length of the arteries. The perivascular nerves consist of a network of axons, terminals, and varicosities, which are distributed mostly in the medial-adventitial and adventitial layers of the arterial wall.

Signals coming in to the kidney travel along efferent nerve pathways and influence renal blood flow, trigger fluid retention, and activate the renin-angiotensin-aldosterone system cascade. Renin is a precursor to the production of angiotensin II, which is a potent vasoconstrictor, while aldosterone regulates how the kidneys process and retain sodium. All of these mechanisms serve to increase blood pressure. Signals coming out of the kidney travel along afferent nerve pathways integrated within the central nervous system, and lead to increased systemic sympathetic nerve activation. Chronic over-activation can result in vascular and myocardial hypertrophy and insulin resistance, causing heart failure and kidney disease.

Previous clinical studies have documented that denervating the kidney has a positive effect for both hypertension and heart failure patients. Journal articles published as early as 1936 review surgical procedures called either sympathectomy or splanchnicectomy, to treat severe hypertension. A 1953 JAMA article by Smithwick et al. presented the results of 1,266 cases of surgical denervation to treat hypertension. The results included radiographic evidence of hearts that had remodeled after the surgery, while also showing significant blood pressure declines. Additional articles published in 1955 and 1964 demonstrated that the concept of using renal denervation to lower blood pressure and treat heart failure was viable. However, given the highly invasive and traumatic nature of the procedure and the advent of more effective antihypertensive agents, the procedure was not widely employed.

More recently, catheter ablation has been used for renal sympathetic denervation. Renal denervation is a method whereby amplified sympathetic activities are suppressed to treat hypertension or other cardiovascular disorders and chronic renal diseases. The objective of renal denervation is to neutralize the effect of renal sympathetic system which is involved in arterial hypertension. The renal sympathetic efferent and afferent nerves lie within and immediately adjacent to the wall of the renal artery. Energy is delivered via a catheter to ablate the renal nerves in the right and left renal arteries in order to disrupt the chronic activation process. As expected, early results appear both to confirm the important role of renal sympathetic nerves in resistant hypertension and to suggest that renal sympathetic denervation could be of therapeutic benefit in this patient population.

In clinical studies, therapeutic renal sympathetic denervation has produced predictable, significant, and sustained reductions in blood pressure in patients with resistant hypertension. Catheters are flexible, tubular devices that are widely used by physicians performing medical procedures to gain access into interior regions of the body. A catheter device can be used for ablating renal sympathetic nerves in therapeutic renal sympathetic denervation to achieve reductions of blood pressure in patients suffering from renal sympathetic hyperactivity associated with hypertension and its progression. Renal artery ablation for afferent and efferent denervation has been shown to substantially reduce hypertension. See, e.g., Henry Krum et al., “Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study,” published online Mar. 30, 2009 at www.thelancet.com. Krum et al. recently reported average reductions of 27 mmHg SBP and 13 mmHg DBP in 34 patients with 12-month follow-up data. In addition, despite having an average SBP baseline of 177 mmHg, 44% of those patients reached controlled blood pressure of <140 mmHg.

SUMMARY

Embodiments of this invention provide renal denervation validation and feedback by detecting renal nerve activity and/or the lack thereof in order to precisely titrate the RF energy dose to achieve the desired renal denervation. The use of RF ablation for denervation is merely illustrative in this disclosure. Other denervation techniques can be used instead, as discussed below.

The first approach assesses the completeness of the renal denervation such as renal artery ablation by measuring the renal nerve plexus electrical activity on the distal side of the lesion site. This activity will be solely intrinsic since there is no external stimulation of the renal nerve plexus. The second approach assesses the completeness of the renal artery ablation by stimulating the renal nerve plexus on the proximal side of the lesion while recording the renal nerve plexus activity on the distal side of the lesion, or vice versa. The third approach verifies with a high degree of confidence that efferent and afferent renal artery nerves have been disconnected. This is accomplished by applying stimulus at a first position in a renal artery and verifying that nerve conduction has been interrupted by evaluating a filtered, detected signal at a second position, and then repeating the procedure with stimulation and detection positions swapped. These approaches are illustrative but not limiting.

Embodiments of the present invention provide a feedback mechanism to control renal denervation (e.g., to titrate RF energy delivery for renal ablation). By assessing the denervation after ablation based on a baseline measurement, one can prevent excessive, unnecessary ablation or denervation. The denervation verification increases the response rate by ensuring that the renal nerve plexus is completely destroyed or at least adequately destroyed based on a preset threshold.

In accordance with an aspect of the present invention, a renal denervation feedback method comprises: performing a baseline measurement of renal nerve plexus electrical activity at a renal vessel; denervating at least some tissue proximate the renal vessel after performing the baseline measurement; performing a post-denervation measurement of renal nerve plexus electrical activity at the renal vessel, after the denervating; and assessing denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel.

In some embodiments, the method further comprises, if a target denervation of the renal vessel is not achieved, repeating the steps of denervating, performing a post-denervation measurement, and assessing denervation of the renal vessel until the target denervation of the renal vessel is achieved. Repeating the steps of denervating, performing a post-denervation measurement, and assessing denervation of the renal vessel comprises adjusting a level of denervation for denervating at least some tissue proximate the renal vessel based on result of assessing denervation of the renal vessel.

In specific embodiments, performing a baseline measurement comprises monitoring baseline afferent signals and baseline efferent signals at the renal vessel without external stimulation to the renal vessel, and performing a post-denervation measurement comprises monitoring post-denervation afferent signals and post-denervation efferent signals at the renal vessel without external stimulation to the renal vessel, after the denervating. Monitoring the baseline afferent signals and baseline efferent signals comprises monitoring baseline afferent compound action potential and baseline efferent compound action potential, counting a number of baseline afferent spikes each representing an afferent compound action potential that exceeds a preset threshold during a specified period of time, and counting a number of baseline efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time. Monitoring the post-denervation afferent signals and post-denervation efferent signals comprises monitoring post-denervation afferent compound action potential and post-denervation efferent compound action potential, counting a number of post-denervation afferent spikes each representing an afferent compound action potential that exceeds the preset threshold during the specified period of time, and counting a number of post-denervation efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time.

In some embodiments, the baseline measurement and the post-denervation measurement occur at a location of the renal vessel proximal of a kidney and proximal of a denervation location for denervating at least some tissue proximate the renal vessel, and the target denervation of the renal vessel is achieved when a ratio of the number of post-denervation afferent spikes to the number of post-denervation efferent spikes is below a preset threshold as compared to a ratio of the number of baseline afferent spikes to the number of baseline efferent spikes. The baseline measurement and the post-denervation measurement occur at a location of the renal vessel proximal of a kidney and distal of a denervation location for denervating at least some tissue proximate the renal vessel, and the target denervation of the renal vessel is achieved when a ratio of the number of post-denervation afferent spikes to the number of post-denervation efferent spikes is above a preset threshold as compared to a ratio of the number of baseline afferent spikes to the number of baseline efferent spikes.

In specific embodiments, performing a baseline measurement comprises supplying nerve stimulation to the renal vessel from one side of a denervation location for denervating at least some tissue proximate the renal vessel and measuring a baseline response of the renal vessel to the nerve stimulation on an opposite side of the denervation location, and performing a post-denervation measurement comprises supplying nerve stimulation to the renal vessel from one side of the denervation location and measuring a post-denervation response of the renal vessel to the nerve stimulation on an opposite side of the denervation location. The same nerve stimulation is supplied from a same first location on the same side of the denervation location for both the baseline measurement and the post-denervation measurement, and the response is recorded on a same second location on the same opposite side of the denervation location for both the baseline measurement and the post-denervation measurement.

In some embodiments, the nerve stimulation is supplied from the proximal side of the denervation location for both the baseline measurement and the post-denervation measurement, and the response is recorded on the distal side of the denervation location for both the baseline measurement and the post-denervation measurement. The nerve stimulation comprises one of electrical stimulation or pharmacological stimulation. Assessing denervation of the vessel comprises: computing a baseline parameter from the baseline response; computing a post-denervation parameter from the post-denervation response; and computing a degree of denervation as a ratio of the post-denervation parameter and the baseline parameter. The target denervation is achieved when the computed ratio falls within a preset range. The baseline parameter comprises a number of baseline spikes each representing a compound action potential that exceeds a preset threshold during a specified period of time as measured in the baseline response. The post-denervation parameter comprises a number of post-denervation spikes each representing a compound action potential that exceeds the same preset threshold during the same specified period of time as measured in the post-denervation response. The target denervation is achieved when the computed ratio falls below a preset number.

In specific embodiments, performing a baseline measurement comprises supplying nerve stimulation to the renal vessel from a first side of a denervation location for denervating at least some tissue proximate the renal vessel and measuring a first baseline response of the renal vessel to the nerve stimulation on a second side of the denervation location opposite the first side, and supplying nerve stimulation to the renal vessel from the second side and measuring a second baseline response of the renal vessel to the nerve stimulation on the first side, and performing a post-denervation measurement comprises supplying nerve stimulation to the renal vessel from the first side and measuring a first post-denervation response of the renal vessel to the nerve stimulation on the second side, and supplying nerve stimulation to the renal vessel from the second side and measuring a second post-denervation response of the renal vessel to the nerve stimulation on the first side. Performing a baseline measurement comprises supplying nerve stimulation to the renal vessel from a first location on the first side of the denervation location and measuring the first baseline response of the renal vessel to the nerve stimulation on a second location on the second side, and supplying nerve stimulation to the renal vessel from the second location and measuring the second baseline response of the renal vessel to the nerve stimulation at the first location. Performing a post-denervation measurement comprises supplying nerve stimulation to the renal vessel from the first location and measuring the first post-denervation response of the renal vessel to the nerve stimulation at the second location, and supplying nerve stimulation to the renal vessel from the second location and measuring the second post-denervation response of the renal vessel to the nerve stimulation at the first location.

In some embodiments, measuring the first baseline response comprises filtering the first baseline response to increase signal-to-noise ratio; measuring the second baseline response comprises filtering the second baseline response to increase signal-to-noise ratio; measuring the first post-denervation response comprises filtering the first baseline response to increase signal-to-noise ratio; and measuring the second post-denervation response comprises filtering the second baseline response to increase signal-to-noise ratio.

In specific embodiments, measuring the first baseline response comprises synchronizing with electrocardiogram to substantially avoid detected signals other than detected signals that are recorded during electrically quiet times; measuring the second baseline response comprises synchronizing with electrocardiogram to substantially avoid detected signals other than detected signals that are recorded during electrically quiet times; measuring the first post-denervation response comprises synchronizing with electrocardiogram to substantially avoid detected signals other than detected signals that are recorded during electrically quiet times; and measuring the second post-denervation response comprises synchronizing with electrocardiogram to substantially avoid detected signals other than detected signals that are recorded during electrically quiet times.

In some embodiments, measuring the first baseline response comprises epoch averaging of multiple epochs relative to stimulus of the nerve stimulation to increase signal-to-noise ratio; measuring the second baseline response comprises epoch averaging of multiple epochs relative to stimulus of the nerve stimulation to increase signal-to-noise ratio; measuring the first post-denervation response comprises epoch averaging of multiple epochs relative to stimulus of the nerve stimulation to increase signal-to-noise ratio; and measuring the second post-denervation response comprises epoch averaging of multiple epochs relative to stimulus of the nerve stimulation to increase signal-to-noise ratio.

In specific embodiments, the nerve stimulation is multiphasic stimulation. The nerve stimulation is supplied via one or more electrodes made of low polarization electrode material. The nerve stimulation has a narrow pulse width selected to reduce stimulus polarization. The nerve stimulation has a pulse width substantially equal to chronaxie of the renal vessel.

In accordance with another aspect of the invention, a renal denervation feedback system comprises: at least one denervation member to denervate at least some tissue proximate the renal vessel; at least one measurement member to perform a baseline measurement of renal nerve plexus electrical activity at a renal vessel before denervation of at least some tissue proximate the renal vessel and to perform a post-denervation measurement of renal nerve plexus electrical activity at the renal vessel after the denervation; and a denervation assessment module to assess denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel.

In some embodiments, a denervation control module is configured, if a target denervation of the renal vessel is not achieved, to instruct operation of the at least one denervation member to repeat denervating at least some tissue proximate the renal vessel, instruct operation of the at least one measurement member to repeat performing a post-denervation measurement, and instruct the denervation assessment module to repeat assessing denervation of the renal vessel, until the target denervation of the renal vessel is achieved.

These and other features and advantages of the present invention will become apparent to those of ordinary skill in the art in view of the following detailed description of the specific embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an example of a flow diagram illustrating the renal denervation verification and feedback method.

FIG. 2 shows an example of the renal denervation site and the measurement site according to a first approach for assessing denervation.

FIG. 3 shows an example of the afferent action potential and efferent action potential.

FIG. 4 shows an example of the renal denervation site, the stimulation site, and the measurement site according to a second approach of assessing denervation.

FIG. 5 shows an example of assessing nerve activity by counting spikes in response to stimulation.

FIG. 6 is a schematic diagram illustrating an example of a denervation system with denervation verification and feedback.

FIG. 7 is a schematic diagram illustrating another example of a denervation system with denervation verification and feedback.

DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings which form a part of the disclosure, and in which are shown by way of illustration, and not of limitation, exemplary embodiments by which the invention may be practiced. In the drawings, like numerals describe substantially similar components throughout the several views. Further, it should be noted that while the detailed description provides various exemplary embodiments, as described below and as illustrated in the drawings, the present invention is not limited to the embodiments described and illustrated herein, but can extend to other embodiments, as would be known or as would become known to those skilled in the art. Reference in the specification to “one embodiment”, “this embodiment”, or “these embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention, and the appearances of these phrases in various places in the specification are not necessarily all referring to the same embodiment. Additionally, in the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. However, it will be apparent to one of ordinary skill in the art that these specific details may not all be needed to practice the present invention. In other circumstances, well-known structures, materials, circuits, processes and interfaces have not been described in detail, and/or may be illustrated in block diagram form, so as to not unnecessarily obscure the present invention.

In the following description, relative orientation and placement terminology, such as the terms horizontal, vertical, left, right, top and bottom, is used. It will be appreciated that these terms refer to relative directions and placement in a two dimensional layout with respect to a given orientation of the layout. For a different orientation of the layout, different relative orientation and placement terms may be used to describe the same objects or operations.

Furthermore, some portions of the detailed description that follow are presented in terms of algorithms, flow-charts and symbolic representations of operations within a computer. These algorithmic descriptions and symbolic representations are the means used by those skilled in the data processing arts to most effectively convey the essence of their innovations to others skilled in the art. An algorithm is a series of defined steps leading to a desired end state or result which can be represented by a flow chart. In the present invention, the steps carried out require physical manipulations of tangible quantities for achieving a tangible result. Usually, though not necessarily, these quantities take the form of electrical or magnetic signals or instructions capable of being stored, transferred, combined, compared, and otherwise manipulated. It has proven convenient at times, principally for reasons of common usage, to refer to these signals as bits, values, elements, symbols, characters, terms, numbers, instructions, or the like. It should be borne in mind, however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities. Unless specifically stated otherwise, as apparent from the following discussion, it is appreciated that throughout the description, discussions utilizing terms such as “processing,” “computing,” “calculating,” “determining,” “displaying,” or the like, can include the actions and processes of a computer system or other information processing device that manipulates and transforms data represented as physical (electronic) quantities within the computer system's registers and memories into other data similarly represented as physical quantities within the computer system's memories or registers or other information storage, transmission or display devices.

The present invention also relates to an apparatus for performing the operations herein. This apparatus may be specially constructed for the required purposes, or it may include one or more general-purpose computers selectively activated or reconfigured by one or more computer programs. Such computer programs may be stored in a computer-readable storage medium, such as, but not limited to optical disks, magnetic disks, read-only memories, random access memories, solid state devices and drives, or any other types of media suitable for storing electronic information. The algorithms and displays presented herein are not inherently related to any particular computer or other apparatus. Various general-purpose systems may be used with programs and modules in accordance with the teachings herein, or it may prove convenient to construct a more specialized apparatus to perform desired method steps. In addition, the present invention is not described with reference to any particular programming language. It will be appreciated that a variety of programming languages may be used to implement the teachings of the invention as described herein. The instructions of the programming language(s) may be executed by one or more processing devices, e.g., central processing units (CPUs), processors, or controllers.

Exemplary embodiments of the invention, as will be described in greater detail below, provide apparatuses and methods for renal denervation verification and feedback.

FIG. 1 is an example of a flow diagram illustrating the renal denervation verification and feedback method. To provide feedback during a renal denervation procedure, the present method involves performing a baseline measurement of renal nerve plexus electrical activity at a renal vessel (step 102). The baseline measurement will be used to assess or verify the level of denervation so as to determine whether the target denervation is achieved or not. After performing the baseline measurement, at least some tissue proximate the renal vessel is denervated (step 104). The denervating typically involves electrical stimulation such as RF ablation, but may employ other methods, including the application of laser, high intensity focused ultrasound (HIFU), cryoablation, other thermal mechanisms for achieving ablation, or mechanical energy to sever or interrupt conduction of the nerve fibers. After the denervating, a post-denervation measurement of renal nerve plexus electrical activity at the renal vessel is performed (step 106). Denervation of the renal vessel is assessed based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel (step 108). The measurement may involve obtaining one or more parameters of the activity or event, such as amplitude, width, or the like, or any combination thereof. Alternatively, the measurement may involve recording or sampling many points to reconstruct an activity or event in time.

If a target denervation of the renal vessel is not achieved, the steps of denervating, performing a post-denervation measurement, and assessing denervation of the renal vessel are repeated until the target denervation of the renal vessel is achieved (step 110). In specific embodiments, this involves adjusting a level of denervation for denervating at least some tissue proximate the renal vessel based on result of assessing denervation of the renal vessel. For example, the RF ablation level can be adjusted based on the result of the denervation assessment.

To carry out the method, a renal denervation feedback system may include at least one denervation member to denervate at least some tissue proximate the renal vessel, at least one measurement member to perform a baseline measurement of renal nerve plexus electrical activity at a renal vessel before denervation of at least some tissue proximate the renal vessel and to perform a post-denervation measurement of renal nerve plexus electrical activity at the renal vessel after the denervation, and a denervation assessment module to assess denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel. In addition, a denervation control module may be provided, if a target denervation of the renal vessel is not achieved, to instruct operation of the at least one denervation member to repeat denervating at least some tissue proximate the renal vessel, instruct operation of the at least one measurement member to repeat performing a post-denervation measurement, and instruct the denervation assessment module to repeat assessing denervation of the renal vessel, until the target denervation of the renal vessel is achieved. Repeating the denervating, performing a post-denervation measurement, and assessing denervation of the renal vessel may include adjusting a level of denervation for denervating at least some tissue proximate the renal vessel based on result of assessing denervation of the renal vessel. The denervation assessment module and the denervation control module may be implemented in electronic circuitry or in software or firmware for execution by a processor, as discussed in further detail below. In the following, various examples of assessing or verifying denervation of the renal vessel are presented.

First Approach

According to a first approach, performing a baseline measurement includes monitoring baseline afferent and efferent signals at the renal vessel without external stimulation to the renal vessel, and performing a post-denervation measurement includes monitoring post-denervation afferent and efferent signals at the renal vessel without external stimulation to the renal vessel, after the denervating.

In a specific example, this approach assesses the completeness of the renal artery denervation or ablation by measuring the renal nerve plexus electrical activity on the distal side of the lesion site. FIG. 2 shows an example of the renal denervation site and the measurement site for assessing denervation. The measurement site 200 is distal of the denervation site 202 and is proximal of the kidney 204. If denervation is complete, this activity will be solely afferent since efferent signals will be blocked at the lesion site. As used herein, the “completeness” of the denervation or ablation may not require complete blockage of signals, but may indicate that a target level of denervation is reached, which can be predetermined or preset by a medical professional, for instance, based on clinical data or the like.

For the baseline measurement, a baseline test is made and the distal activity of the renal nerve plexus is recorded. This will become the baseline measurement. After performing the denervation or ablation of the renal artery plexus, a post-denervation test is made and the distal activity of the renal nerve plexus is recorded. In this example, a lesion completeness score is generated, which is equal to the ratio of a baseline score (baseline measurement) and a post-denervation score (post-denervation measurement). If the lesion completeness score exceeds a predetermined threshold; then the lesion is deemed complete; otherwise, the denervation is repeated and another lesion completeness score is generated until the predetermined threshold is met. The predetermined threshold can be determined in pre-clinical studies or the like.

FIG. 3 shows an example of the afferent action potential and efferent action potential. The action potential direction between the brain and the kidney can be determined by looking at the morphological polarity of the electrogram. While both action potentials look alike as recorded on an oscilloscope, the phases are reversed polarity. The action potential direction can be determined by using bipolar measurement electrodes that are organized longitudinally at the measurement site 200.

There are various ways to quantify the nerve plexus activity. In one example, during each nerve activity measurement period (baseline or post-denervation), afferent and efferent “spikes” will be counted. Spikes represent compound action potential levels that meet or exceed a predetermined threshold level. The ratio of the number of afferent spikes and the number of efferent spikes will be computed for both periods and assigned as the lesion completeness score. That is, monitoring the baseline afferent signals and baseline efferent signals includes monitoring baseline afferent compound action potential and baseline efferent compound action potential, counting a number of baseline afferent spikes each representing an afferent compound action potential that exceeds a preset threshold during a specified period of time, and counting a number of baseline efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time. Monitoring the post-denervation afferent signals and post-denervation efferent signals includes monitoring post-denervation afferent compound action potential and post-denervation efferent compound action potential, counting a number of post-denervation afferent spikes each representing an afferent compound action potential that exceeds the preset threshold during the specified period of time, and counting a number of post-denervation efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time.

In one specific embodiment, the baseline measurement and the post-denervation measurement occur at a location of the renal vessel proximal of a kidney and distal of a denervation location for denervating at least some tissue proximate the renal vessel (as seen in FIG. 2). The target denervation of the renal vessel is achieved when a ratio of the number of post-denervation afferent spikes to the number of post-denervation efferent spikes is above a preset threshold as compared to a ratio of the number of baseline afferent spikes to the number of baseline efferent spikes.

In another specific embodiment, the baseline measurement and the post-denervation measurement occur at a location of the renal vessel proximal of a kidney and proximal of a denervation location for denervating at least some tissue proximate the renal vessel (e.g., by swapping the measurement site 200 and the denervation site 202 in FIG. 2). The target denervation of the renal vessel is achieved when a ratio of the number of post-denervation afferent spikes to the number of post-denervation efferent spikes is below a preset threshold as compared to a ratio of the number of baseline afferent spikes to the number of baseline efferent spikes.

Second Approach

According to a second approach, performing a baseline measurement includes supplying nerve stimulation to the renal vessel from one side of a denervation location for denervating at least some tissue proximate the renal vessel and measuring a baseline response of the renal vessel to the nerve stimulation on an opposite side of the denervation location, and performing a post-denervation measurement includes supplying nerve stimulation to the renal vessel from one side of the denervation location and measuring a post-denervation response of the renal vessel to the nerve stimulation on an opposite side of the denervation location. Examples of nerve stimulation include electrical stimulation and pharmacological stimulation such as the injection of neurotoxins.

In a specific example, the method assesses the completeness of the renal artery denervation or ablation by stimulating the renal nerve plexus on the proximal side of the lesion while measuring the renal nerve plexus activity on the distal side of the lesion. FIG. 4 shows an example of the renal denervation site, the stimulation site, and the measurement site according to the second approach of assessing denervation. The stimulation site 400 is proximal of the denervation site 402, and the measurement site 404 is distal of the denervation site 402 and is proximal of the kidney 406. Before the denervation, a baseline test is made by stimulating the renal artery plexus and simultaneously measuring the distal activity. This will become the baseline measurement. After perform the denervation or ablation of the renal artery plexus, a post-denervation test is made by stimulating the renal artery plexus and simultaneously measuring the distal activity to obtain the post-denervation measurement. A lesion completeness score is generated as the ratio of the baseline score (baseline measurement) and the post-denervation score (post-denervation measurement). If the lesion completeness score exceeds a predetermined threshold, then the lesion is complete; otherwise, the denervation is repeated and another lesion completeness score is generated until the predetermined threshold is met. The predetermined threshold can be determined in pre-clinical studies or the like.

In one specific embodiment, the same nerve stimulation is supplied from the same first location on the same side of the denervation location for both the baseline measurement and the post-denervation measurement, and the response is recorded on the same second location on the same opposite side of the denervation location for both the baseline measurement and the post-denervation measurement (as seen in FIG. 4).

In another specific embodiment, the nerve stimulation is supplied from the proximal side of the denervation location for both the baseline measurement and the post-denervation measurement, and the response is recorded on the distal side of the denervation location for both the baseline measurement and the post-denervation measurement (as seen in FIG. 4).

Assessing denervation of the vessel includes computing a baseline parameter from the baseline response, computing a post-denervation parameter from the post-denervation response, and computing a degree of denervation as a ratio of the post-denervation parameter and the baseline parameter. The target denervation is achieved when the computed ratio falls within a preset range.

There are various ways to quantify the nerve plexus activity. One way of assessing nerve activity is to count what are known as “spikes” during a specified period of time. Spikes represent compound action potential levels that meet or exceed a predetermined threshold level. FIG. 5 shows an example of assessing nerve activity by counting spikes in response to stimulation. The first recorded activity for the baseline measurement shows a number of spikes in response to the stimulation. The second recorded activity for the post-denervation measurement shows little or no spikes in response to the stimulation for a successful denervation, for which stimulation is not conducted or at least substantially not conducted after the denervating. The third recorded activity for the post-denervation measurement shows spikes in response to the stimulation for an unsuccessful denervation, for which stimulation is still conducted after the denervating.

In one example, the baseline parameter includes a number of baseline spikes each representing a compound action potential that exceeds a preset threshold during a specified period of time as measured in the baseline response. The post-denervation parameter includes a number of post-denervation spikes each representing a compound action potential that exceeds the same preset threshold during the same specified period of time as measured in the post-denervation response. The target denervation is achieved when the computed ratio falls below a preset number. The preset number can be determined by clinical studies or the like.

Third Approach

According to a third approach, performing a baseline measurement includes supplying nerve stimulation to the renal vessel from a first side of a denervation location for denervating at least some tissue proximate the renal vessel and measuring a first baseline response of the renal vessel to the nerve stimulation on a second side of the denervation location opposite the first side, and supplying nerve stimulation to the renal vessel from the second side and measuring a second baseline response of the renal vessel to the nerve stimulation on the first side, and performing a post-denervation measurement includes supplying nerve stimulation to the renal vessel from the first side and measuring a first post-denervation response of the renal vessel to the nerve stimulation on the second side, and supplying nerve stimulation to the renal vessel from the second side and measuring a second post-denervation response of the renal vessel to the nerve stimulation on the first side.

Referring to FIG. 4, the stimulation site 400 is on the proximal side (first side) of the denervation site 402, and the measurement site 404 is on the distal side (second side) of the denervation site 402. This configuration is used to record the first response (baseline or post-denervation). To record the second response (baseline or post-denervation), the stimulation site 400 and the measurement site 404 are swapped to opposite sides from the configuration shown in FIG. 4. According to the third approach, denervation verification test in both efferent and afferent directions is used to verify complete, bidirectional denervation.

In a specific embodiment, performing a baseline measurement includes supplying nerve stimulation to the renal vessel from a first location on the first side of the denervation location and measuring the first baseline response of the renal vessel to the nerve stimulation on a second location on the second side, and supplying nerve stimulation to the renal vessel from the second location and measuring the second baseline response of the renal vessel to the nerve stimulation at the first location. Performing a post-denervation measurement includes supplying nerve stimulation to the renal vessel from the first location and measuring the first post-denervation response of the renal vessel to the nerve stimulation at the second location, and supplying nerve stimulation to the renal vessel from the second location and measuring the second post-denervation response of the renal vessel to the nerve stimulation at the first location.

The heart and other muscles of the body generate noise that can interfere with subject verification. Various signal processing methods can be used to increase the signal-to-noise ratio of the detected signal (DS) resulting from the verification test stimulus. Measuring the first baseline response includes filtering the first baseline response to increase signal-to-noise ratio. Measuring the second baseline response includes filtering the second baseline response to increase signal-to-noise ratio. Measuring the first post-denervation response includes filtering the first baseline response to increase signal-to-noise ratio. Measuring the second post-denervation response includes filtering the second baseline response to increase signal-to-noise ratio. Various filtering techniques can be used, including the use of a band pass filter to filter out EKG noise and other background noise from the patient and the surroundings. In one example, a band pass filter in the range of about 500 to about 5,000 or up to about 10,000 Hz may be used.

One technique to improve signal-to-noise involves synchronizing the measurement with the electrocardiogram to include only DS signals that are recorded during electrically quiet times (e.g., ST segment). Cardiosynchronous processing of denervation test signals reduces the effect of cardiogenic noise. Denervation test signal epoch averaging of N epochs is used to improve signal-to-noise by √{square root over ( )}N. For instance, signal averaging of 400 signal epochs can improve signal-to-noise by a factor of 20. Measuring the first baseline response, measuring the second baseline response, measuring the first post-denervation response, and measuring the second post-denervation response each include synchronizing with electrocardiogram to substantially avoid detected signals other than detected signals that are recorded during electrically quiet times. For example, measuring the first baseline response, measuring the second baseline response, measuring the first post-denervation response, and measuring the second post-denervation response each include epoch averaging of multiple epochs relative to stimulus of the nerve stimulation to increase signal-to-noise ratio. The above filters are used to improve denervation test detected signal-to-noise ratio to improve the confidence of denervation verification.

Another feature is to limit the effect of stimulus polarization on the measurement. Since neural pulses travel many meters per second, it is necessary to sense the evoked neural response within microseconds after the stimulus. Polarization afterpotentials are minimized by using a bipolar or quadpolar or pentapolar stimulation pulse that has no DC content and tends to rapidly neutralize polarization effects.

In certain preferred embodiments, the nerve stimulation is multiphasic stimulation. Multiphasic stimuli tend to have little polarization afterpotential. The nerve stimulation is supplied via one or more electrodes made of low polarization electrode material. Low polarization stimulation electrodes are used to minimize polarization afterpotentials. Examples include Ag/AgCl, TiN, IrOx, and platinized platinum. For a discussion of identifying stimulus parameters and electrode geometries that were effective in selectively stimulating targeted neuronal populations within the central nervous system, see Cameron C. McIntyre & Warren M. Grill, “Selective Microstimulation of Central Nervous System Neurons,” Annals of Biomedical Engineering. 2000; 28:219-233.

The nerve stimulation has a narrow pulse width selected to reduce or minimize stimulus polarization (e.g., about 50 microseconds). In one specific embodiment, the nerve stimulation has a pulse width substantially equal to chronaxie of the renal vessel. Chronaxie is the tissue-excitability parameter that permits choice of the optimum stimulus pulse duration for stimulation of any excitable tissue. When the chronaxie of nerve is measured, it is important to recognize that most nerve trunks contain bundles of fibers having different diameters and hence different propagation velocities, and with each fiber group having its own chronaxie. A strength-duration curve can be plotted for each fiber group, from which the chronaxies can be determined. See Leslie A. Geddes, “Accuracy Limitations of Chronaxie Values,” IEEE Transactions on Biomedical Engineering. January 2004; 51(1):176-181.

Exemplary Systems

FIG. 6 is a schematic diagram illustrating an example of a denervation system with denervation verification and feedback. A renal vessel 600 may include efferent nerves for efferent conduction and/or afferent nerves for afferent in the directions shown. Note that when a nerve is stimulated, it will conduct in both directions regardless of whether the nerve is efferent or afferent. Therefore, one may characterize one direction of conduction as orthodromic (e.g., in the normal direction for that nerve) instead of efferent and the opposite direction of conduction as antidromic (e.g., in the direction opposite the normal direction for that nerve) instead of afferent.

In FIG. 6, a pair of stimulating electrodes 602 are provided to stimulate efferent nerves or nerves for orthodromic and efferent conduction (e.g., with the stimulus as shown) under the control of a processor 604 via a D/A converter 606, and another pair of detecting or measurement electrodes 608 are provided to record nerve plexus electrical activity to determine whether there is orthodromic or efferent conduction. The measurement electrodes 608 are coupled via an amplifier 610 (e.g., having a 10⁵ gain), a band pass filter or BPF 612 (e.g., about 500-10,000 Hz), and an A/D converter 614 to the processor 604. The processor 604 has circuitries and/or executes software modules stored in memory 620 in order to control the nerve stimulating and measuring and to control operation of a denervation apparatus 624 for denervating at least some tissue proximate the renal vessel 600 at a location between the stimulating electrodes 602 and the measurement electrodes 608 (e.g., in the form of ablation electrodes on the nerves). The denervation apparatus 624 may include, for example, a denervation member in the form of one or more RF electrodes and an RF energy source. For illustrative purposes, FIG. 6 shows a denervation assessment module 626 to assess denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel 600 and a denervation control module 628 to control the nerve denervation by the denervation apparatus 624. If a target denervation of the renal vessel 600 is not achieved, the denervation control module 628 instructs operation of the denervation apparatus 624 to repeat denervating at least some tissue proximate the renal vessel, instructs operation of the measurement electrodes 608 to repeat performing a post-denervation measurement, and instructs the denervation assessment module 626 to repeat assessing denervation of the renal vessel 600, until the target denervation of the renal vessel 600 is achieved.

The denervation system in FIG. 6 can be used to carry out the procedure of the first approach (without activating the stimulating electrodes 602), the procedure of the second approach, and partially the procedure of the third approach (with the need to swap the stimulating and measuring positions). A denervation system that is more suitable for the third approach is shown in FIG. 7.

It will be understood by those of ordinary skill in the art that the various methods and systems described herein can be performed either intravascularly, extravascularly, or a combination approach using both intravascular and extravascular approaches in combination. In the intravascular approach, a suitable ablation catheter is advanced through the patient's vasculature and into the renal artery adjacent the afferent and efferent renal nerves.

FIG. 7 is a schematic diagram illustrating another example of a denervation system with denervation verification and feedback. A renal vessel 700 has coupled thereto a plurality of electrodes 701-706. FIG. 7 shows a 6-electrode system, but the number of electrodes can vary in other embodiments. In FIG. 7, all six electrodes are used for ablation, while two pairs of electrodes 701-702 and 705-706 are alternately used for stimulating and measuring to perform denervation verification. Denervation by ablation is performed by connecting an RF amplifier 710 via leads to the six electrodes 701-706 in sequence using six switches 711-716 which are connected to the output of the RF amplifier 710 and an RF oscillator 718 and controlled by a computer or controller 720. The computer 720 has a processor, a memory, and various circuitries and modules to control denervation of the renal vessel 700 and perform denervation verification and feedback, including pulse generation, signal control, switch control, filtering, signal averaging, etc. For example, the computer 720 may include a denervation assessment module and a denervation control module such as those shown in FIG. 6.

After ablation, inactivation of the renal nerves of the renal vessel 700 is verified by stimulating a pair of electrodes 701-702 or 705-706 (bipolarly or unipolarly), alternately, using D/A converters 733, 734 and switches connected to their outputs (pairs of switches corresponding to pairs of stimulating electrodes 701-702 and 705-706), and by “listening” for a conducted signal by selecting a pair of electrodes 705-706 or 701-702, alternately, to connect to a measurement amplifier 740 via switches (pairs of switches corresponding to pairs of measurement electrodes 705-706 and 701-702). The measurement amplifier 740 is connected to an analog or digital band pass filter or BPF 746 or directly to an A/D converter 748 that is read by the computer 720. The BPF 746 can be eliminated if such filtering is done in the computer 720. A control panel for the system may include user controls 752 and display 754. According to the third approach, the denervation assessment module in the computer 720 contains an algorithm to analyze the response “seen” by the measurement amplifier 740 and decides if the renal nerves are blocked and the stimulation/response verification can be performed on different electrodes to assure all nerves are blocked. If more ablation is needed, the denervation control module in the computer 720 can advise the user or perform additional ablation automatically until there is no afferent or efferent nerve signal continuity.

In the description, numerous details are set forth for purposes of explanation in order to provide a thorough understanding of the present invention. However, it will be apparent to one skilled in the art that not all of these specific details are required in order to practice the present invention. It is also noted that the invention may be described as a process, which is usually depicted as a flowchart, a flow diagram, a structure diagram, or a block diagram. Although a flowchart may describe the operations as a sequential process, many of the operations can be performed in parallel or concurrently. In addition, the order of the operations may be re-arranged.

From the foregoing, it will be apparent that the invention provides methods, apparatuses and programs stored on computer readable media for renal denervation verification and feedback. Additionally, while specific embodiments have been illustrated and described in this specification, those of ordinary skill in the art appreciate that any arrangement that is calculated to achieve the same purpose may be substituted for the specific embodiments disclosed. This disclosure is intended to cover any and all adaptations or variations of the present invention, and it is to be understood that the terms used in the following claims should not be construed to limit the invention to the specific embodiments disclosed in the specification. Rather, the scope of the invention is to be determined entirely by the following claims, which are to be construed in accordance with the established doctrines of claim interpretation, along with the full range of equivalents to which such claims are entitled. 

What is claimed is:
 1. A renal denervation feedback method comprising: performing a baseline measurement of intrinsic renal nerve plexus electrical activity at a renal vessel by monitoring compound action potentials including baseline afferent and efferent signals; denervating at least some tissue proximate the renal vessel after performing the baseline measurement; performing a post-denervation measurement of intrinsic renal nerve plexus electrical activity at the renal vessel by monitoring post-denervation compound action potentials including post-denervation afferent and efferent signals, after the denervating; assessing denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel; and determining the denervation is complete when the post-denervation compound action potentials include afferent signals below a threshold value.
 2. The renal denervation feedback method of claim 1, further comprising, if the denervation is not complete: repeating the steps of denervating, performing a post-denervation measurement, and assessing denervation of the renal vessel until the post-denervation compound action potentials are solely efferent signals.
 3. The renal denervation feedback method of claim 2, wherein repeating the steps of denervating, performing a post-denervation measurement, and assessing denervation of the renal vessel comprises: adjusting a level of denervation for denervating at least some tissue proximate the renal vessel based on a result of assessing denervation of the renal vessel.
 4. The renal denervation feedback method of claim 1, wherein performing the baseline measurement of renal nerve plexus electrical activity comprises: counting a number of baseline afferent spikes each representing an afferent compound action potential that exceeds a preset threshold during a specified period of time; and counting a number of baseline efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time, and wherein performing a post-denervation measurement of renal nerve plexus electrical activity comprises: counting a number of post-denervation afferent spikes each representing an afferent compound action potential that exceeds the preset threshold during the specified period of time; and counting a number of post-denervation efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time.
 5. The renal denervation feedback method of claim 1, wherein performing a baseline measurement comprises supplying nerve stimulation to the renal vessel from one side of a denervation location for denervating at least some tissue proximate the renal vessel and measuring a baseline response of the renal vessel to the nerve stimulation on an opposite side of the denervation location; and wherein performing a post-denervation measurement comprises supplying nerve stimulation to the renal vessel from one side of the denervation location and measuring a post-denervation response of the renal vessel to the nerve stimulation on an opposite side of the denervation location.
 6. The renal denervation feedback method of claim 1, wherein monitoring compound action potentials including baseline afferent and efferent signals comprises using a plurality of bi-polar measurement electrodes to measure the baseline afferent and efferent signals.
 7. The renal denervation feedback method of claim 1, wherein monitoring compound action potentials including post-denervation afferent and efferent signals comprises using a plurality of bi-polar measurement electrodes to measure the post-denervation afferent and efferent signals.
 8. The renal denervation feedback method of claim 1, wherein denervating at least some tissue proximate the renal vessel after performing the baseline measurement comprises using at least one denervation electrode to denervate the at least some tissue.
 9. A renal denervation feedback system comprising: at least one denervation member to denervate at least some tissue proximate the renal vessel; at least one measurement member to perform a baseline measurement of intrinsic renal nerve plexus electrical activity, including baseline afferent and efferent signals, at a renal vessel before denervation of at least some tissue proximate the renal vessel and to perform a post-denervation measurement of renal nerve plexus electrical activity, including post-denervation afferent and efferent signals, at the renal vessel after the denervation, the baseline and post-denervation measurements acquired by monitoring compound action potentials; and a denervation assessment module to assess denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel, wherein the denervation assessment module is configured to determine the denervation is complete when the post-denervation compound action potentials include afferent signals below a threshold value.
 10. The renal denervation system of claim 9, wherein, if the denervation is not complete, the denervation assessment module is further configured to direct the at least one denervation member to repeat denervation of the at least some tissue.
 11. The renal denervation system of claim 10, wherein the denervation assessment module is further configured to direct the at least one denervation member to adjust a level of denervation for denervating the at least some tissue proximate the renal vessel.
 12. The renal denervation system of claim 9, wherein the at least one measurement member is configured to perform the baseline measurement of renal nerve plexus electrical activity by: counting a number of baseline afferent spikes each representing an afferent compound action potential that exceeds a preset threshold during a specified period of time; and counting a number of baseline efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time, and wherein the at least one measurement member is configured to perform the post-denervation measurement of renal nerve plexus electrical activity by: counting a number of post-denervation afferent spikes each representing an afferent compound action potential that exceeds the preset threshold during the specified period of time; and counting a number of post-denervation efferent spikes each representing an efferent compound action potential that exceeds the preset threshold during the specified period of time.
 13. The renal denervation feedback system of claim 9, wherein the at least one measurement member comprises a plurality of bi-polar measurement electrodes.
 14. The renal denervation feedback system of claim 9, wherein the at least one denervation member comprises at least one denervation electrode. 